Severe Chronic Constipation Diagnosis and Management

Critical Secondary Causes to Exclude

The American College of Gastroenterology recommends ruling out hypothyroidism, a common reversible cause of constipation, with TSH testing 1, 2
Hypercalcemia can present with constipation, abdominal pain, and nausea, and should be checked with serum calcium levels 1, 2
Hypokalemia impairs colonic motility and should be assessed with a basic metabolic panel 1, 2
Diabetes mellitus can cause autonomic neuropathy affecting gut motility 1, 2

The National Comprehensive Cancer Network recommends systematically reviewing all medications for constipating effects, including antacids, anticholinergic drugs, and antiemetics 1, 2

The American Gastroenterological Association recommends discontinuing docusate immediately, as it provides no therapeutic benefit and has been shown to be less effective than stimulant laxatives alone 3, 4
For constipation with significant abdominal pain/bloating, linaclotide (Linzess) 145 mcg once daily is superior to osmotic laxatives for addressing both constipation and visceral pain 4, 5
For severe motility dysfunction, prucalopride (Motegrity) 2 mg once daily is a selective 5-HT4 receptor agonist that enhances colonic motility through high-amplitude propagated contractions 5

The American College of Gastroenterology recommends ruling out mechanical bowel obstruction before escalating laxative therapy, particularly given the prominent fecal loading on x-ray 1, 2, 6
The combination of left lower quadrant pain, nausea, and severe constipation warrants consideration of impaction requiring manual disimpaction or glycerin suppositories 1, 2

The American Gastroenterological Association recommends starting with polyethylene glycol (PEG) as first-line pharmacological therapy after discontinuing any constipating medications, and if symptoms persist after 4-12 weeks, escalate to secretagogues (linaclotide 145 mcg or lubiprostone) or the prokinetic prucalopride rather than continuing to increase laxative doses 7, 8, 9, 10

The European Society for Medical Oncology and other guideline societies recommend osmotic laxatives, particularly polyethylene glycol (PEG), as the first-line pharmacological agents because they are inexpensive, widely available, well-tolerated, and effective for chronic idiopathic constipation 11, 12

If symptoms do not respond adequately to PEG after 4-12 weeks, the American Gastroenterological Association recommends escalating to prescription agents rather than continuing to increase osmotic laxative doses 7, 8

The American Gastroenterological Association recommends performing anorectal testing in patients who do not respond to first-line laxatives to identify defecatory disorders (dyssynergic defecation, pelvic floor dysfunction) 13

The American Gastroenterological Association notes that complete symptom resolution is often not achievable, and patients must understand that drug treatment is just one component of a multimodal approach, with the efficacy of all drugs for constipation being modest 11, 12